The argument has sharpened because the stakes have. With initial denial rates at 11.8% nationally and climbing, rework costs running $48 to $64 per claim, and net revenue leakage hitting $48.4 billion in 2025, the denial management function is no longer a cost center to minimize — it's a profit lever to optimize. The question isn't whether to invest in it. It's whether to build the capability or buy it.
The vendor market has matured into distinct models. Understanding them is the prerequisite to the decision.
Three Vendor Models
The RCM outsourcing market clusters around three approaches. First, the full-service operators: R1 RCM, the largest pure-play, which takes over the revenue cycle end-to-end under long-term contracts with performance guarantees; and Conifer Health Solutions, Tenet Healthcare's RCM arm, which runs the same playbook. These are effectively outsourced revenue cycle departments — your staff, your systems, their management. The pitch is scale economics: centralized expertise, standardized processes, and technology investment no single hospital could justify.
Second, the technology-led platforms: Waystar, which went public in 2024 and has built its position on cloud-based claims and denial management software with an expanding AI layer; and FinThrive, formed from the merger of nThrive and TransUnion Healthcare, pairing revenue cycle software with data analytics. These vendors sell capability rather than headcount — the hospital keeps its team, the platform makes the team faster. The pitch is augmentation: your people, supercharged.
Third, the specialists: denial management boutiques, prior authorization firms, and eligibility vendors that take a slice of the cycle rather than the whole thing. The pitch is focus: they do one thing, at volume, better than a generalist team.
The Build-vs-Buy Calculus
The honest math starts with cost to collect. Industry benchmarks put mature in-house revenue cycle operations at 3 to 5% of net revenue. Outsourced arrangements typically price as a percentage of collections — often in the 4 to 8% range depending on scope, with performance-based components. On pure cost, in-house usually wins for large systems with scale; outsourcing usually wins for smaller hospitals that can't amortize the technology and expertise across enough volume.
But cost to collect is the wrong first question. The right first question is capability: can you hire, retain, and manage the denial management talent you need? Revenue cycle faces the same labor market as the rest of healthcare — experienced billers, certified coders, and denial specialists are scarce, and turnover in billing departments routinely runs high. An in-house team that can't stay staffed doesn't have a cost advantage; it has a vacancy problem that shows up as aging A/R.
The second question is technology. The payer side has industrialized: AI-driven claims editing, automated prior authorization review, algorithmic underpayment. A hospital working denials with manual queues and spreadsheet tracking is bringing a knife to a drone fight. The build case requires real technology investment — claim scrubbers with payer-specific edits, denial analytics with root-cause trending, workflow automation. The buy case gets that technology on day one, amortized across the vendor's client base.
The third question is accountability. This is where outsourcing contracts earn or lose their keep. The best agreements tie vendor compensation to outcomes — denial rate reduction, net collection rate, days in A/R — with baseline measurements and shared upside. The worst are cost-plus arrangements where the vendor gets paid regardless of performance. A hospital that outsources without outcome-based terms hasn't bought capability; it's rented headcount at a markup.
When Outsourcing Wins — and When It Doesn't
Outsourcing wins in three scenarios. Small and midsize hospitals without the scale for a best-in-class in-house operation get immediate access to technology and expertise. Systems in turnaround — where the revenue cycle is already distressed, A/R is aged, and denials are unworked — get a reset faster than rebuilding internally. And organizations facing chronic staffing instability get continuity that the labor market won't provide.
In-house wins in three others. Large systems with scale can run the function at lower cost and keep the institutional knowledge — payer relationships, contract nuances, physician dynamics — that vendors take with them when contracts end. Organizations with strong existing teams and modern technology have no capability gap to fill; outsourcing would add margin without adding value. And hospitals where the revenue cycle is deeply integrated with clinical operations — academic medical centers, complex specialty systems — often find that the handoffs between vendor and clinical staff cost more than they save.
The hybrid model, increasingly common, splits the difference: keep patient access, coding, and payer relations in-house; outsource the high-volume, rules-based work like eligibility verification and standard denial follow-up; buy the technology platform regardless. It preserves control where control matters and buys scale where scale matters.
One caution that applies to every model: the vendor's incentives are not the hospital's incentives. A vendor paid as a percentage of collections wants volume; a hospital wants clean claims. A vendor measured on denial overturns wants appeals; a hospital wants prevention. Structure the relationship around the outcomes you actually want — clean claim rate, final denial rate, net collection rate — and audit against them relentlessly. The contract is the strategy.